Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN), an AI-focused oncology company using its RADR® and Open-Medicine platforms, will host a webcast to review its second quarter 2026 operating and financial results on Friday, August 14, 2026 at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time.
According to Lantern Pharma, management will discuss results for the quarter ended June 30, 2026 and provide guidance on upcoming milestones, clinical trials, and developments related to its AI platforms. The webcast will be led by President and CEO Panna Sharma, alongside other management team members, and a replay will be available on the company’s investor relations website.
Lantern Pharma (Nasdaq: LTRN) has created a separate company, Open-Medicine AI (OMAI), to commercialize and expand its multi-agentic AI co-scientist platform previously launched as withZeta.ai. Lantern has executed commercial licensing agreements granting OMAI access to withZeta.ai-related models, data, algorithms, and other assets and personnel, following Board approval and aligning with the framework of Lantern’s May 2026 registered direct financing.
OMAI will advance the multi-agent system first proven in oncology and rare cancers and extend it into additional disease areas, supported by AI Centers of Excellence in Dallas, Texas and Bengaluru, India. The platform integrates specialized AI agents, rare-cancer knowledge bases, ZetaOmics™ multi-omic analytics, and generative chemistry tools to support real-world drug discovery and development in a global AI market projected to exceed $10 billion by 2030.
Lantern Pharma (NASDAQ: LTRN) reported that an investigator-initiated, EMA-cleared Phase 1b/2 trial of its lead candidate LP-184 (zirdafulven) will begin in advanced or metastatic urothelial (bladder) cancer at Rigshospitalet in Copenhagen. The trial targets patients who have progressed after standard regimens, including enfortumab vedotin plus pembrolizumab, and uses a dual-biomarker precision-oncology strategy combining PTGR1 overexpression with DNA-damage-repair deficiency (NER/HR) to enrich for tumors likely to respond. Designed as an open-label study with dose optimization followed by a Simon two-stage Phase 2, it will enroll up to approximately 39 patients, with objective response rate as the primary endpoint and multiple survival and quality-of-life outcomes as secondary measures. Lantern estimates about 137,500 third-line-eligible patients globally each year and a potential $3+ billion opportunity in this setting by 2035.
Lantern Pharma (NASDAQ: LTRN) received a USPTO Notice of Allowance for U.S. Patent Application No. 17/230,821 covering biomarker-guided use of LP-184 (zirdafulven) in solid tumors. The allowed claims address selecting and treating patients with ovarian, primary liver, kidney, or thyroid cancers whose tumors show elevated expression of three genes: PTGR1, PTPN14, and ASPH.
According to Lantern Pharma, its RADR® AI platform helped identify PTGR1 overexpression and low expression of multiple DNA damage repair (DDR) genes as predictors of LP-184 sensitivity. In a completed 63-patient Phase 1a trial in recurrent or refractory advanced solid tumors, LP-184 achieved a 45% disease control rate among patients treated at or above the effective therapeutic dose. LP-184 is planned for multiple precision oncology Phase 1b/2 trials in advanced aggressive and rare cancers during 2026, and the company intends to further expand LP-184 patent coverage.
Lantern Pharma (NASDAQ: LTRN) launched ZetaOmics, an autonomous “Computational Biologist” module within withZeta.ai for multi-omic cancer analysis. It accesses over 615,000 curated cancer samples across 11 data sources and embeds domain intelligence into 14 tools to design, run, and audit rigorous bioinformatics workflows.
ZetaOmics enters early access with leading bioinformatics teams and collaborators, targeting rare and pediatric cancers while also serving all cancer types. Lantern aims to open new markets, partnerships, and subscription-based, non-dilutive revenue in AI-enabled oncology R&D.
Lantern Pharma (NASDAQ: LTRN) reported updated Phase 2 HARMONIC™ data for LP-300 in EGFR Exon 21 L858R-mutant NSCLC after TKI therapy. L858R patients treated through up to six cycles reached 8.9-month median PFS (8.4 months overall; n=15), with >70% tumor reduction in evaluable patients and a 77% clinical benefit rate.
Across 31 patients, LP-300 added no clinically meaningful toxicity beyond carboplatin/pemetrexed, with low serious treatment-related events in cross-trial comparisons versus amivantamab regimens. An FDA-cleared amendment extends LP-300 dosing to eight cycles, and enrollment is concentrating on L858R patients. Lantern is using these data for partnering discussions at ASCO 2026.
Lantern Pharma (NASDAQ: LTRN) reported a successful FDA Type C interaction for its Phase 2 HARMONIC™ trial of LP-300 in never-smokers with advanced NSCLC.
The FDA raised no objections to protocol changes: enriching for EGFR exon 21 L858R patients, extending LP-300 dosing to eight cycles, and moving to a single-arm, enriched design.
Preliminary data show an 8.3‑month median progression-free survival in L858R patients and an early U.S. cohort with 86% clinical benefit and 43% objective response, with one complete response lasting over two years.
Lantern Pharma (NASDAQ:LTRN) reported Q1 2026 results marked by cost reductions, pipeline progress, and new AI initiatives. R&D spend fell 47% year-over-year and Q1 net loss declined 27% while multiple oncology programs advanced.
Cash, equivalents, and marketable securities were $6.3M on March 31, 2026; combined with about $4.4M in May 14 financing proceeds, pro forma liquidity is expected to fund operations into the middle of Q1 2027. Lantern launched its commercial multi-agentic AI platform withZeta.ai, expanded predictBBB.ai into a broader molecular intelligence service, obtained a successful FDA Type C meeting outcome for the LP-300 HARMONIC trial, and received FDA IND clearance for a pediatric CNS cancer trial via subsidiary Starlight Therapeutics. Lantern also plans to separate withZeta.ai into an independent entity under CEO Panna Sharma.
Lantern Pharma (NASDAQ: LTRN) closed a registered direct offering of 2,135,923 common shares (or pre-funded warrants) at $2.06 per share, raising approximately $4.4 million in gross proceeds, before fees.
In a concurrent private placement, Lantern issued unregistered warrants for up to 2,135,923 shares at $2.27, potentially adding about $4.85 million in gross proceeds if fully exercised. Proceeds are intended for working capital and general corporate purposes.
Lantern Pharma (NASDAQ: LTRN) entered a definitive agreement for a registered direct offering of 2,135,923 common shares or pre-funded warrants at $2.06 per share, raising about $4.4 million in gross proceeds.
Concurrent private warrants for up to 2,135,923 shares at $2.27 could add $4.85 million. Lantern also plans an independent AI entity based on its withZeta.ai platform.